SCHEMBL1997046

SCHEMBL1997046

CC(C)(C)[C@@]1(C)CN(Cc2ccc(NS(=O)(=O)c3ccc(-c4ccc(F)cc4)cc3)cc2)CCN1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KMT2A Q03164 2/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.44
MLNR O43193 1/20 0.43
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 3/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 3/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ABCB1 P08183 1/20 0.41
FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995199 0.90 MLNR (0.58) MEN1NPC1RAB9AKMT2APTGDR2
SCHEMBL2003279 0.88 PRKAA2 (0.46) MEN1NPC1RAB9AKMT2APTGDR2
SCHEMBL1998344 0.87 MLNR (0.44) MEN1NPC1RAB9AKMT2APTGDR2
SCHEMBL2002044 0.84 MLNR (0.42) MEN1NPC1RAB9AKMT2APTGDR2
SCHEMBL1996929 0.83 KDM4E (0.46) MEN1NPC1RAB9AKMT2APTGDR2
SCHEMBL1996027 0.83 S1PR1 (0.39) MEN1RAB9AKMT2APTGDR2MLNR
SCHEMBL1999298 0.81 PRKAA2 (0.43) MEN1NPC1RAB9AKMT2AMLNR
SCHEMBL1995582 0.80 MLNR (0.57) MEN1KMT2AMLNRALDH1A1MAPK1
SCHEMBL1998242 0.79 MLNR (0.60) KMT2AMLNRALDH1A1GAASMN1; SMN2
SCHEMBL1999248 0.79 MLNR (0.60) KMT2AMLNRALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964597-B2 Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases GLAXO GROUP LIMITED (GB) 2011-06-21 US disclosed